Contents
On this page
- Definition of application and its determinants
- Dosage forms and their requirements of the API
- Variation in development burden by therapeutic class
- Protein therapeutics and molecule-level formulation constraints
- Carriers as part of the active principle
- Gene and cell therapy as applications without a conventional drug substance
- Reporting an application study to permit evaluation of the formulation choice
- Claims not supported by current evidence
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · Applications of APIs
Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes
An active pharmaceutical ingredient (API) becomes useful only once a route and a dosage form have been selected for it, and that selection is constrained by solubility, permeability, stability, dose and target tissue rather than by preference. This article maps the application space: which dosage forms suit which API properties, how therapeutic class alters the development burden, and where the carrier has become the product.
Two papers may describe the same molecule and yet share little else. One concerns a crystalline solid with a dissolution problem; the other concerns a monoclonal antibody at 150 mg/mL that must remain stable in a prefilled syringe. “Application” denotes the point at which the physical properties of the API meet a route of administration, and most formulation failures arise from a mismatch at that point rather than from a synthesis problem. For any application study, the central question for reviewers is the justification of this form, for this molecule, by this route.
Learning objectives
- How dosage form choice follows from API properties — solubility, dose, permeability, stability, first-pass metabolism
- What each route of administration demands of the active substance, stated as constraints rather than advantages
- How development burden differs by therapeutic class, with the capitalised cost figures that quantify the gap
- Where the delivery system has become inseparable from the active principle — nanocarriers, lipid nanoparticles, vectors, cells
- What an application or formulation-development paper must state so the choice can be judged rather than taken on trust
- Which claims in this area are not supported by the evidence as it stands
Common misconceptions
- “Oral is the default and everything else is a fallback.” Oral administration is the default only for molecules that survive the gut and the liver at an acceptable dose. For a high-dose, poorly permeable or acid-labile substance, parenteral administration is the primary option rather than a fallback.
- “Development cost is roughly the same across therapy areas.” Wouters, McKee and Luyten, in JAMA, report a median capitalised cost of $765.9 million for nervous system agents against $2,771.6 million for antineoplastic and immunomodulating agents.
- “Nanocarriers solve solubility problems.” Nanocarriers relocate the problem rather than eliminate it. Zheng and colleagues, reviewing polymeric nanomicelles in clinical trials and on the market in Chinese Chemical Letters, document how few of the many reported systems reach approval.
- “Gene and cell therapies are a niche application.” Ginn and colleagues, in The Journal of Gene Medicine, report that 68.3% of gene therapy trials worldwide to 2023 targeted cancer, which makes it the dominant application space in oncology research rather than a niche.
- “This is a separate topic from what an API is.” The two topics are continuous. The API definition page covers what the substance is and how it is specified; this article addresses how it is applied.
Definition of application and its determinants
This article concerns the step that follows the existence of the substance: the selection of a route, a dosage form and a release profile that the molecule can support. The decision is governed by a short list of properties, none of which is negotiable. Aqueous solubility and dissolution rate determine whether a solid oral form can deliver sufficient drug. Permeability determines whether dissolved drug crosses the gut wall. First-pass metabolism determines whether an oral dose reaches the circulation in a usable fraction. Chemical stability in acid, in water and towards oxidation rules out whole classes of form. Dose size determines whether a unit can be swallowed at all. The target tissue determines whether systemic exposure is the objective or the problem.
ICH Q8(R2) provides the formal structure for this reasoning through the quality target product profile: the required performance of the product is stated, the critical quality attributes that follow are derived, and the formulation and process are then designed to control them 3. Comoglu and Ozyilmaz set out the same quality-by-design logic in their chapter on pharmaceutical product development 10. The value of this framing for an author is that it makes the application argument explicit rather than implicit: the author does not assert that a form is good but demonstrates that it meets a profile stated in advance.
Where the substance has not yet been fixed, the choice runs in the opposite direction: form requirements constrain which candidate is taken forward. The page on selecting materials for drug development works through that direction.
Dosage forms and their requirements of the API
The table below serves as a working map and should be read as a set of constraints: each form has entry conditions that the active substance must meet, and the most common error in application papers is proposing a form for a molecule that fails one of them and then reporting the resulting poor performance as a formulation finding.
Solid oral forms dominate because they are inexpensive, stable and self-administered, but they impose the most demanding dissolution requirement. The classic responses — particle-size reduction, salt selection, amorphous solid dispersion, solubilising surfactants, lipid-based systems — all work by changing dissolution or apparent solubility, and all of them bring a stability cost, which Narang and colleagues treat as a primary determinant of solid dosage form stability 24. The orodispersible route is a special case driven by swallowing difficulty: Jain and colleagues, in Polymers in Medicine, review co-processed excipients for fast-disintegrating tablets, where the form must disperse in under 3 min in the buccal cavity before swallowing, which constrains both the excipient set and the drug load.
Parenteral forms remove the absorption problem and replace it with a sterility, tonicity and solubility-at-pH problem. Topical and transdermal forms require permeation through a barrier designed to prevent it, which in practice restricts them to potent molecules of modest molecular weight. Inhaled forms require a defined aerodynamic particle size and a drug that tolerates the physical stress of aerosolisation. None of these is a mere preference; each is a prerequisite.
Dosage form against the API properties it requires
| Dosage form | What the API must have | What rules it out | Typical formulation response |
|---|---|---|---|
| Immediate-release solid oral (tablet, capsule) | Adequate aqueous solubility and dissolution rate; acid and enzymatic stability; acceptable permeability; dose that fits a swallowable unit | High-dose poorly soluble compounds; acid-labile substances; peptides and proteins | Salt selection, particle-size reduction, surfactant, amorphous solid dispersion, lipid-based system |
| Modified-release solid oral | A therapeutic window that benefits from sustained exposure; solubility across the gastrointestinal pH range; an absorption window long enough to exploit | Compounds absorbed only in the proximal small intestine; very short half-life with high clearance | Matrix or reservoir systems, functional coating, osmotic pump |
| Orodispersible tablet | Low dose; palatable or maskable taste; compatibility with highly hygroscopic superdisintegrants | High drug load; strongly bitter actives without a masking route | Co-processed excipients; dispersion required in under 3 min in the buccal cavity |
| Oral liquid | Solution or suspension stability over shelf life; palatability | Hydrolytically labile compounds; actives needing high ethanol or co-solvent levels in paediatric use | Buffering, preservation, suspending agents, taste masking |
| Parenteral (IV, IM, SC) | Solubility at an injectable pH and tonicity; sterilisability or aseptic processing; stability in solution or as a lyophilisate | Compounds requiring large volumes subcutaneously; actives unstable in aqueous solution without lyophilisation | Co-solvents, cyclodextrins, lyophilisation, high-concentration protein formulation |
| Topical and transdermal | Potency high enough for a small delivered dose; modest molecular weight; favourable partitioning into stratum corneum | Large or highly hydrophilic molecules; high systemic dose requirements | Penetration enhancers, vehicle optimisation, occlusive or reservoir patches |
| Inhaled | Tolerance of aerosolisation stress; achievable aerodynamic particle size in the respirable range; local tolerability | Actives requiring high delivered mass; irritant substances | Micronisation or spray drying, carrier blends, propellant or dry powder device selection |
| Nanoparticulate and carrier-based | Loadable into the carrier at useful efficiency; stable during carrier manufacture | Actives that destabilise the carrier or leak rapidly from it | Polymeric micelles, liposomes, lipid nanoparticles — where the carrier becomes part of the product |
Constraints compiled from the formulation and delivery literature cited on this page, including Jain and colleagues in Polymers in Medicine on fast-disintegrating tablets, Narang and colleagues on excipient interaction and solid dosage form stability, Jiskoot and colleagues and Hu and colleagues on high-concentration protein formulation, and Liu, Tang and Zheng and colleagues on nanoparticulate carriers. The 3 min dispersion requirement for orodispersible tablets is as stated by Jain and colleagues; the remaining entries are qualitative constraints, not quantified thresholds.
Variation in development burden by therapeutic class
APIs are not applied in a uniform cost environment, and the differences between therapy areas are sufficiently large to alter research planning. Wouters, McKee and Luyten, in JAMA, estimated a mean capitalised research and development cost per approved agent of $1,559.1 million, with a 95% confidence interval from $1,271.0 million to $1,893.8 million 17. Disaggregated by therapeutic class, the median capitalised cost was $765.9 million for nervous system agents against $2,771.6 million for antineoplastic and immunomodulating agents — a difference of roughly a factor of 3.6 between two of the most active areas 17.
This figure requires a caveat. The same study could assemble usable cost data for only a minority of approvals in the period, so the class-level medians rest on small subsets and should be read as indicative of a real gap rather than as precise estimates. What they do establish is that the economics of applying an API in oncology and immunology differ in kind from the economics in neurology, which bears on trial size, biomarker requirements and the cost of failure late in development 17.
Source: Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. Class medians rest on the subset of approvals with usable cost data and are indicative of the gap rather than precise.
Protein therapeutics and molecule-level formulation constraints
For monoclonal antibodies and other protein actives the application question changes in nature. The molecules cannot be given orally, the systemic dose is often large, and the commercial and clinical pressure is towards subcutaneous self-administration in a small injection volume. This necessitates high concentration, which is where protein formulations fail. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, set out the unresolved problems directly: viscosity rising non-linearly with concentration, aggregation and opalescence, interfacial stress during filling and delivery, and injection-site tolerability 14. Hu and colleagues, in the AAPS series, give the practical development view of the same constraints 16.
The excipient set is different as a result — buffers, sugars, amino acids, surfactants and sometimes viscosity-reducing agents, selected for colloidal and conformational stability rather than for compaction or disintegration 14,16. Our excipient page covers that divergence, and bio-macromolecules covers the characterisation side. The most accurate summary of the field is that of Jiskoot and colleagues: high-concentration subcutaneous formulation remains an open development problem, not a solved one 14.
Carriers as part of the active principle
There is a class of application where the delivery system is no longer an excipient system. Liu and colleagues, in Chinese Chemical Letters, review nanoparticle drug delivery systems for diagnosis and treatment; Tang and colleagues, in Progress in Polymer Science, cover polymeric nanostructured materials for biomedical use; Zheng and colleagues review polymeric nanomicelles that have reached clinical trials or the market. Taken together, these reviews make two points that are easily overlooked. The first is that the carrier changes biodistribution, which means it changes efficacy and toxicity, which means it is pharmacologically consequential 11,22. The second is that the attrition between reported systems and approved products is severe — the literature contains far more described nanocarriers than the clinic does 12.
Lipid nanoparticles for mRNA constitute the clearest current example. Estapé Senti and colleagues, in Advanced Drug Delivery Reviews, describe mRNA delivery for cancer immunotherapy, where the ionisable lipid, the helper lipid, the cholesterol and the PEG-lipid together determine whether the nucleic acid reaches the cytoplasm at all 8. Describing those components as excipients is technically defensible but practically misleading, because the particle itself is the product. The same applies to viral vectors, where Shchaslyvyi and colleagues, in Pharmaceuticals, survey approved gene therapy products by vector type, and Alhakamy and colleagues, in Drug Discovery Today, trace the preclinical-to-clinical path 9,15. Our page on nano-biomaterials covers how these carriers have to be characterised.
Gene and cell therapy as applications without a conventional drug substance
In advanced therapies there is often no API in any useful sense. The active principle is a vector carrying a transgene, or a population of engineered cells whose potency is defined by a functional assay rather than by an assay against a reference standard. Ginn and colleagues, in The Journal of Gene Medicine, give the application profile for gene therapy trials worldwide to 2023: 68.3% targeted cancer and 13.1% inherited monogenic disease 7. This distribution is significant because it indicates that the dominant application of gene therapy is oncology, where it competes with and complements conventional agents rather than substituting for them in rare disease alone 7.
Chimeric antigen receptor T-cell therapy is the best-documented example of a cell therapy. Hu, Korsos and Palomba, in Frontiers in Oncology, review CAR T-cell therapy for aggressive B-cell lymphomas, and Lulla and colleagues, in Clinical Advances in Hematology and Oncology, cover its use in non-Hodgkin lymphoma 6,19. For the purposes of scientific writing, the key difference is that the “dose” is a cell number with a viability and phenotype specification, the manufacturing is patient-specific, and the release criteria are biological 6. None of the specification vocabulary from small-molecule work transfers, and borrowing it makes a methods section harder to assess rather than easier.
Source: Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721.
Reporting an application study to permit evaluation of the formulation choice
An application paper makes a claim of the form “this form, for this molecule, by this route, achieves this”. What a reviewer needs in order to assess it is the target profile against which the formulation was designed, the API properties that constrained the options, the alternatives considered and rejected, with the reasons, and the performance test with its discriminating power demonstrated. Most submitted application papers supply the fourth and skip the first three, which turns a design argument into an assertion.
Two specific requirements merit emphasis. The target profile should be stated before the results, because a profile written after the fact cannot fail. The performance test should also be shown to discriminate: a dissolution method under which every formulation passes provides information about the method, not the formulations. The comparison below presents the opening of a formulation-development paper in the two versions that reviewers routinely encounter.
The opening of a formulation-development paper, two ways
An assertion
Because of its poor aqueous solubility, a solid dispersion of the drug was prepared to improve dissolution. The optimised formulation showed significantly higher dissolution than the pure drug and the marketed tablet, demonstrating the suitability of the approach.
What was the target? No profile, so “suitability” has nothing to be judged against and the study cannot fail.
How poor is “poor”? No solubility value and no dose, so the reader cannot see whether a solid dispersion was even necessary.
What else was tried? Alternatives are invisible, so the choice looks like a preference rather than a decision.
Does the dissolution method discriminate? Unaddressed — a non-discriminating method makes any difference look like a result.
Is the amorphous form stable? The central risk of the approach chosen is not mentioned.
A design argument
The target profile was an immediate-release tablet delivering 50 mg, with not less than 80% dissolved in 30 min in 900 mL of pH 6.8 phosphate buffer, and no change in solid form or dissolution after 6 months at 40 degrees C and 75% relative humidity. The drug substance is a BCS class II compound with equilibrium solubility of 12 micrograms per millilitre at pH 6.8, giving a dose-to-solubility ratio incompatible with that target as the crystalline free base. Three options were evaluated against the profile: micronisation, which raised 30 min dissolution to 41% and was rejected as insufficient; a sodium salt, rejected after the salt reverted to the free base on storage at 75% relative humidity; and a spray-dried amorphous dispersion in HPMC-AS, which met the profile at 94% in 30 min. The dissolution method was shown to discriminate, giving 41%, 58% and 94% for the micronised, physical-mixture and dispersion formulations respectively under identical conditions. Physical stability of the amorphous form was confirmed by XRPD at 6 months, which was the acceptance criterion the salt failed.
The profile is stated first, with numeric acceptance criteria, so the work can succeed or fail on its own terms.
The solubility and dose are given, so the magnitude of the problem is visible rather than asserted.
Rejected options are reported with the reason, which is what turns the result into a design argument.
The dissolution method is shown to discriminate across formulations under identical conditions.
The known failure mode of the chosen approach — recrystallisation of the amorphous form — is tested and reported against a stated criterion.
The second version contains one extra experiment and three extra sentences. What it adds is falsifiability: a reader can agree or disagree with the choice, which is the only way an application claim can carry weight.
Claims not supported by current evidence
Three claims recur in this literature and are weaker than they appear. First, that nanocarrier systems reliably improve clinical outcomes: Zheng and colleagues’ survey of polymeric nanomicelles in trials and on the market documents a steep gap between the number of systems described and the number approved, and the reviews by Liu and colleagues and Tang and colleagues are explicit that translation, not fabrication, is the bottleneck 11,12,22. Second, that in vitro release predicts in vivo performance across carrier types — no source here establishes that, and for nanoparticulate systems the relationship is weak enough that in vitro release should be presented as a quality control tool rather than as a surrogate.
Third, that development cost figures can be applied to a specific programme. The class-level medians from Wouters and colleagues — $765.9 million for nervous system agents, $2,771.6 million for antineoplastic and immunomodulating agents — rest on the subset of approvals with usable data, and the authors acknowledge this 17. They are evidence of a real difference between therapy areas, not a budgeting instrument.
For completeness, the device side of the application question follows a separate regulatory logic; see material selection for medical devices, and where light is the therapeutic or diagnostic agent rather than a molecule the relevant page is applications of optoelectronic devices. See also the concepts and definitions hub for where these terms sit relative to each other.
Key points
Key points
Applying an API entails matching a route and dosage form to properties the molecule already possesses — solubility, permeability, stability, dose and target tissue — and each form imposes entry conditions rather than offering advantages. Therapeutic class alters the development burden substantially: Wouters and colleagues report median capitalised costs of $765.9 million for nervous system agents against $2,771.6 million for antineoplastic and immunomodulating agents. For proteins the constraint moves into the molecule, where high-concentration subcutaneous formulation remains unresolved. For nanocarriers, vectors and cells the carrier or construct is the product, and small-molecule terminology ceases to be adequate. Reports should state the target profile first, describe the rejected options and demonstrate that the performance test discriminates.
Application to your study
Application to your study
- Write the target product profile before the results section. Dose, route, release criterion with a numeric acceptance limit, and stability requirement. A profile written afterwards cannot be failed.
- State the API properties that constrained the choice. Measured solubility with the medium and pH, dose, stability liabilities, permeability class if known — not the adjective “poorly soluble”.
- Report the options you rejected and why. Two or three lines for each option suffice; this converts an assertion into a design argument.
- Demonstrate that the performance test discriminates. The test should be shown to separate formulations expected to differ; a method under which every formulation passes is uninformative.
- Test the failure mode of the chosen approach. Recrystallisation for amorphous systems, salt disproportionation for salts, leakage for carriers, aggregation for proteins.
- Use a single API lot across the formulation comparison and state this. Otherwise material and formulation effects are confounded.
- Quote therapeutic-class cost figures with their source and caveat. The class medians rest on a subset of approvals with usable data; cite them as evidence of a gap, not as a budget.
- For carriers, vectors and cell products, replace small-molecule API terminology. The construct, its potency assay and its release criteria should be described in the terms used in the field.
Frequently asked questions
The API definition page deals with what the substance is and how it must be specified: identity, salt, solid form, impurity limits, particle size, characterisation and the boundaries against intermediates and the drug product. This page deals with what happens next — which routes and dosage forms the substance can support, what each form requires of it, how the development burden varies by therapeutic class, and where the delivery system has become part of the active principle. The definition page addresses what must be stated about the material; this page addresses which form the material should take and how that choice should be defended.
Four factors, in approximate order of how frequently they prevent oral administration. Dissolution: enough drug must dissolve in gastrointestinal fluid volumes at the required dose, which is a function of solubility and dose together rather than solubility alone. Permeability: dissolved drug must cross the gut wall. Stability: the substance must survive gastric acid and intestinal enzymes. First-pass metabolism: enough must survive hepatic extraction to give usable systemic exposure. Peptides and proteins fail on at least three of the four, which is why they are parenteral. A high-dose, poorly soluble compound fails on the first, and the usual responses — salt, particle-size reduction, amorphous dispersion, lipid system — all trade dissolution gain against stability risk.
The best available estimate indicates that it does, with an important caveat. Wouters, McKee and Luyten, in JAMA, report a mean capitalised cost per approved agent of $1,559.1 million (95% CI $1,271.0–$1,893.8 million), and by class a median of $765.9 million for nervous system agents against $2,771.6 million for antineoplastic and immunomodulating agents. The caveat is that usable cost data existed for only a minority of approvals in the period, so the class medians rest on small subsets. They should be read as establishing that a large real difference exists — driven by trial size, biomarker requirements and late-stage attrition — not as figures on which to base the planning of a specific programme.
They are a legitimate option with a poor translation record, and the literature acknowledges this openly. Liu and colleagues, in Chinese Chemical Letters, review nanoparticle delivery systems for diagnosis and treatment; Tang and colleagues cover polymeric nanostructured materials in Progress in Polymer Science; Zheng and colleagues specifically survey polymeric nanomicelles that reached clinical trials or the market, and the gap between systems described and systems approved is large. The carrier also changes biodistribution, so it changes efficacy and toxicity rather than only solubility. A nanocarrier should be treated as a new product with its own characterisation and safety burden, not as a minor formulation adjustment.
Because several failure modes worsen together as concentration rises. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, name them: viscosity increasing non-linearly, which affects both manufacturing and injectability; aggregation and opalescence driven by protein–protein interactions; interfacial stress during filling, shipping and delivery; and injection-site tolerability at the volumes and excipient levels required. Hu and colleagues, in the AAPS series, describe the same constraints from a development standpoint. Both reviews present the problem as open. Formulation studies in this area should report viscosity, subvisible and submicron particle data and an interfacial stress challenge, not only a monomer percentage.
Oncology, by a wide margin. Ginn and colleagues, in The Journal of Gene Medicine, report that of gene therapy trials worldwide to 2023, 68.3% targeted cancer and 13.1% inherited monogenic disease. This finding corrects the common assumption that gene therapy is primarily a rare-disease technology. Shchaslyvyi and colleagues, in Pharmaceuticals, survey the approved products and their vector types, and Alhakamy and colleagues, in Drug Discovery Today, describe the preclinical-to-clinical path. For CAR T-cell therapy specifically, Hu, Korsos and Palomba review aggressive B-cell lymphomas in Frontiers in Oncology.
Target profile, then constraints, then options, then selection, then verification. The profile should be stated with numeric acceptance criteria before any results; the measured API properties that limited the options should be given; the alternatives evaluated, and the reason each was rejected, should be reported; the selected formulation should be presented against the profile; and verification should use a performance test shown to discriminate, together with a test of the known failure mode of the chosen approach. ICH Q8(R2) supplies the formal version of this logic through the quality target product profile and critical quality attributes, and Comoglu and Ozyilmaz set out the same quality-by-design framing in their chapter on pharmaceutical product development.
Not across carrier types, and not for nanoparticulate systems on the evidence available here. For conventional immediate-release solid oral forms a discriminating dissolution method can be a useful surrogate when a correlation has been established for that specific product. For polymeric micelles, liposomes and lipid nanoparticles no source on this page establishes a general in vitro–in vivo relationship, and the release measurement itself is method-dependent because separating released from encapsulated drug is non-trivial. In vitro release for these systems should be presented as a quality control and comparability tool, with an explicit statement that it is not offered as a predictor.
References
- U.S. Food and Drug Administration, CDER Office of Generic Drugs. FDA's Inactive Ingredient Database (IID) Program & AI Consideration. FDA FY2026 Generic Drug Science and Research Initiatives Public Workshop. 2026. read 9 October 2026. fda.gov
- U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
- Comoglu T, Ozyilmaz ED. Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives. Pharmaceutical Development and Technology. 2025;30(1):1-9. doi:10.1080/10837450.2024.2441181 read 9 October 2026. doi.org/10.1080/10837450.2024.2441181
- Hu B, Korsos V, Palomba ML. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas. Frontiers in Oncology. 2024;14:1394057. doi:10.3389/fonc.2024.1394057 read 9 October 2026. doi.org/10.3389/fonc.2024.1394057
- Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721. doi:10.1002/jgm.3721 read 9 October 2026. doi.org/10.1002/jgm.3721
- Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
- Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
- Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
- Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters. 2022. doi:10.1016/j.cclet.2022.05.032 read 9 October 2026. doi.org/10.1016/j.cclet.2022.05.032
- Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, Wang C. An overview of polymeric nanomicelles in clinical trials and on the market. Chinese Chemical Letters. 2021;32(1):243-257. doi:10.1016/j.cclet.2020.11.029 read 9 October 2026. doi.org/10.1016/j.cclet.2020.11.029
- Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
- Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
- Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: From preclinical development to clinical application. Drug Discovery Today. 2021;26(7):1602-1619. doi:10.1016/j.drudis.2021.03.021 read 9 October 2026. doi.org/10.1016/j.drudis.2021.03.021
- Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
- Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
- Lulla PD, Hill LC, Ramos CA, Heslop H. The use of chimeric antigen receptor T cells in patients with non-hodgkin lymphoma. Clinical Advances in Hematology and Oncology. 2018;16(5):375-386. read 9 October 2026. scholars.houstonmethodist.org
- Milic J, Calija B, Krajisnik D. Excipients functionality: Importance and compendial status. Arhiv za farmaciju. 2016;66(2):71-90. doi:10.5937/arhfarm1602071M read 9 October 2026. doi.org/10.5937/arhfarm1602071M
- Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
- Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B, Chen X. Polymeric nanostructured materials for biomedical applications. Progress in Polymer Science. 2016;60:86-128. doi:10.1016/j.progpolymsci.2016.05.005 read 9 October 2026. doi.org/10.1016/j.progpolymsci.2016.05.005
- Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
- Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
- M Saifee, N Inamda, D Dhamecha, A Rathi. Drug polymorphism: a review. International Journal of Health Research. 2010;2(4). doi:10.4314/ijhr.v2i4.55423 read 9 October 2026. doi.org/10.4314/ijhr.v2i4.55423
- Lu J, Rohani S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs). Current Medicinal Chemistry. :884-905. doi:10.2174/092986709787549299 read 9 October 2026. doi.org/10.2174/092986709787549299
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes. Pubrica. https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/
Pubrica Academy. “Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/.
Pubrica Academy (2026) Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/ (Accessed: 15 October 2026).
Pubrica Academy. “Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/
Pubrica Academy, ‘Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/> accessed 15 October 2026.
Pubrica Academy. Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/
Pubrica Academy, “Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/
@misc{applications_of_active_pharmaceutical__2026,
author = {{Pubrica Academy}},
title = {Applications of Active Pharmaceutical Ingredients Across Dosage Forms and Therapeutic Classes},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/applications-of-active-pharmaceutical-ingredients/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Application rationale block for a formulation or delivery paper
This block should be completed before the introduction is written. It becomes the first two paragraphs of the paper and the structure of the results section. The rejected-options rows are the part reviewers most often find missing.
APPLICATION RATIONALE BLOCK
1. TARGET PRODUCT PROFILE (write this first; do not revise it after the results)
Indication / population ............ ______________________________
Route of administration ............ ______________________________
Dosage form ........................ ______________________________
Dose per unit ...................... ______________________________
Release criterion (numeric) ........ ______ % in ______ min in ______________
Stability requirement .............. ______ months at ______ degrees C / ______ % RH
Patient-facing constraint .......... [ ] swallowability [ ] injection volume
[ ] device use [ ] palatability [ ] none
2. API PROPERTIES THAT CONSTRAIN THE CHOICE (measured, with conditions)
Aqueous solubility ................. ______ at pH ______, medium ______________
Dose-to-solubility ratio ........... ______________________________
Permeability / BCS class if known .. ______________________________
Solid form as supplied ............. ______________________________
Stability liabilities .............. [ ] acid [ ] hydrolysis [ ] oxidation
[ ] photolysis [ ] form conversion
Particle size (d10 / d50 / d90) .... ______ / ______ / ______
3. OPTIONS EVALUATED
Option 1 ........................... ______________________________
Result against the profile ....... ______________________________
Rejected / carried forward, why .. ______________________________
Option 2 ........................... ______________________________
Result against the profile ....... ______________________________
Rejected / carried forward, why .. ______________________________
Option 3 ........................... ______________________________
Result against the profile ....... ______________________________
Rejected / carried forward, why .. ______________________________
4. PERFORMANCE TEST
Method and conditions .............. ______________________________
Discrimination demonstrated by ..... ______________________________
(report values for formulations expected to differ, same conditions)
Sink conditions / surfactant justified? ______________________________
5. FAILURE MODE OF THE SELECTED APPROACH (test it, report it)
[ ] Amorphous system -> recrystallisation, by XRPD at ______ months
[ ] Salt -> disproportionation at high RH
[ ] Carrier -> drug leakage, carrier size and PDI change on storage
[ ] Protein -> aggregation, subvisible particles, viscosity at use concentration
[ ] Modified release -> dose dumping with food or alcohol
Result: ______________________________
6. MATERIAL CONTROL
Single API lot used throughout? .... [ ] yes [ ] no (state where it changed)
Excipient grades, functions, suppliers and lots recorded? [ ] yes
Container closure system stated? ... [ ] yes
7. WHAT THE PAPER MUST NOT CLAIM
[ ] No efficacy inference from dissolution alone
[ ] No in vivo prediction from in vitro release for a nanocarrier
[ ] No cost or market claim beyond what the cited source supports Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s medical writing and regulatory writing teams structure application and formulation-development papers around the target profile rather than the result, covering constraints, rejected options, a discriminating performance test and a test of the failure mode of the chosen approach. Where the work involves carriers, vectors or cell products, the terminology and critical quality attributes are matched to the product class rather than adapted from a small-molecule framework.